Renal transplantation in HBsAg+ patients: Is lamivudine your "final answer"?

Journal of Clinical Gastroenterology

Volumn 37, Issue 1, 2003, Pages 9-11

  Fontana, Robert J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS C; HUMAN; KIDNEY TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; POSTOPERATIVE CARE; RENAL DIALYSIS;

EID: 0038613656     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200307000-00005     Document Type: Editorial

References (30)

1. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. 1996;62:297-299.
2. Alter MJ, Kellerman S, Preventing hepatitis B and Hepatitis C virus infections in end-stage renal disease patients: back to basics. Hepatology. 1999;29:291-293.
3. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.
4. Han DJ, Kim TH, Park SK, et al. Results on preemptive or prophylactic treatment of lamviduine in HBsAg + renal allograft recipients: Comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation. 2001;71:387-394.
5. Park S, Yang WS, Lee YS, et al. Outcome of renal transplantation in hepatitis B surface antigen positive patients after renal transplantation. Nephrol Dial Transplant. 2001;16:2222-2228.
6. Chan TM, Fang GX, Tang CSO. et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246-1252.
7. Ilan Y, Nagler A, Adler R, et al. Adoptive transfer of immunity to hepatitis B virus after T-cell depleted allogeneic bone marrow transplantation. Hepatoplogy. 1993;18:246-252.
8. Lo CM, Fung JT, Lau GK, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology, 2003;37:36-43.
9. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplant candidates: Clinical practice guidelines. Am J Transplantation. 2001;1(Suppl 2):38-43.
10. Kletzmayr J, Watschinger B. Chronic hepatitis B virus infection in renal transplant recipients. Sem Nephrology. 2002;22:375-389.
11. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis. 2000;38:1009-1015.
12. Fairley CK, Mijch A, Gust ID, et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis B e antigen and/or HBV DNA positive. Transplantation. 1991;52:497-500.
13. Perrilo R, Mason AL. Interferon therapy of hepatitis B. Gastroenterol Clin North Am. 1994;23:581-601.
14. Thervet E. Pol S. Legendre C. et al. Low-dose recombinant leukocyte interferon a treatment of hepatitis C viral infection in renal transplant recipients: A pilot study. Transplantation. 1994;58:625-630.
15. Kletzmayr J, Watschinger B, Muller C, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation. 2000;70:1404-1407.
16. Perrillo R. Hepatitis B and renal transplantation: securing the sword of Damocles. Hepatology. 2002;36:1041-1044.
17. Schmilovitz-Weiss H. Melzer E. Tur-Kaspa R, Ben-Ari Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastro. 2003;(In Press)
18. Johnson MA, Verpooten GA, Daniel MJ, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of hemodialysis. Br J Clin Pharmacol. 1998;46:21-27.
19. Fontaine H, Thiers V, Chertin Y, et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation. 2000;69:2090-2094.
20. Puchhammer-Stockl E, Mandl CW, Kletzmayr J, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Inf Dis. 2000;181:2063-2066.
21. Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology. 1988;94:151-156.
22. Liaw YF, Tsai S, Chien R, et al. Prednisolone priming enhances Thl response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology. 2000;32:604-609.
23. Fontana RJ, Hann HW, Wright T, et al. A Multicenter study of Lamivudine Treatment in 33 patients with hepatitis B after Liver Transplantation. Liver Transplantation. 2001;7:504-510.
24. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine resistant hepatitis B virus in a renal transplant recipient. Transplantation. 1999;68:1912-1914.
25. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
26. Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 2002;36:464-473.
27. Perillo R, Schiff E, Yoshida E, et al. Adefovir dipvoxil for the treatment of lamivudine resistant hepatitis B mutants. Hepatology. 2000;32:129-135.
28. Tillmann HL, Bock CT, Bleck JS, et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transplantation. 2003;9:191-196.
29. Levine S, Hernandez D, Yamanaka G, et al. Efficacy of entecavir against lamivudine resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents & Chemo. 2002;46:2525-2532.
30. Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine resistant hepatitis B mutants strongly affects viral replication. Hepatology. 2002;36:507-508.